Cabaletta Bio, Inc. $CABA Stock Holdings Increased by Jennison Associates LLC

Jennison Associates LLC raised its holdings in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) by 4.8% during the 4th quarter, Holdings Channel reports. The fund owned 8,905,699 shares of the company’s stock after purchasing an additional 408,162 shares during the period. Jennison Associates LLC owned approximately 0.09% of Cabaletta Bio worth $19,503,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. bought a new stake in Cabaletta Bio during the 4th quarter valued at $34,000. Jones Financial Companies Lllp bought a new stake in Cabaletta Bio during the 3rd quarter valued at $47,000. SG Americas Securities LLC raised its stake in Cabaletta Bio by 44.0% during the 4th quarter. SG Americas Securities LLC now owns 30,629 shares of the company’s stock valued at $67,000 after acquiring an additional 9,365 shares in the last quarter. Comerica Bank raised its stake in Cabaletta Bio by 2,292.1% during the 1st quarter. Comerica Bank now owns 41,599 shares of the company’s stock valued at $58,000 after acquiring an additional 39,860 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Cabaletta Bio by 695.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 51,036 shares of the company’s stock valued at $78,000 after acquiring an additional 44,621 shares in the last quarter.

Cabaletta Bio Stock Performance

CABA opened at $2.94 on Friday. Cabaletta Bio, Inc. has a one year low of $1.11 and a one year high of $3.78. The stock’s fifty day moving average is $3.08 and its 200-day moving average is $2.70. The company has a market capitalization of $327.28 million, a PE ratio of -1.29 and a beta of 3.18.

Cabaletta Bio (NASDAQ:CABA) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05. On average, equities research analysts forecast that Cabaletta Bio, Inc. will post -1.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CABA. Guggenheim lifted their target price on Cabaletta Bio from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Monday, April 20th. Morgan Stanley cut their target price on Cabaletta Bio from $14.00 to $13.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 24th. Finally, Wall Street Zen downgraded Cabaletta Bio from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Cabaletta Bio has a consensus rating of “Moderate Buy” and an average price target of $17.00.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.